Lyell Immunopharma, Inc.

1.99 USD
+0.05 (+2.58%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Lyell Immunopharma, Inc. stock is down -15.32% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 December’s closed higher than November. 100% of analysts rate it a buy.

About Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc. engages in developing T cell therapies for patients with solid tumors. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers. The company entered into research and development collaboration with GlaxoSmithKline for NY-ESO-1 program.